Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 3/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2748683 | 0.89 | PDE4A (0.42) | PDE4APDE4CPDE4DADORA2AADORA1 | |
| SCHEMBL2749412 | 0.86 | PDE4A (0.36) | PDE4APDE4CPDE4DCA1CA2 | |
| SCHEMBL31496161 | 0.82 | PDE4A (0.49) | PDE4APDE4CPDE4DADORA2AADORA1 | |
| SCHEMBL2748382 | 0.82 | PDE4A (0.49) | PDE4APDE4CPDE4DADORA2AADORA1 | |
| SCHEMBL18791386 | 0.80 | PDE4A (0.43) | PDE4APDE4CPDE4DADORA2AADORA1 | |
| SCHEMBL2749443 | 0.78 | PDE4A (0.43) | PDE4APDE4CPDE4DADORA2AADORA1 | |
| SCHEMBL2749053 | 0.78 | PDE4A (0.39) | PDE4APDE4CPDE4DADORA2AADORA1 | |
| SCHEMBL18770029 | 0.78 | PDE4A (0.40) | PDE4APDE4CPDE4DADORA2AADORA1 | |
| SCHEMBL18769912 | 0.78 | PDE4A (0.40) | PDE4APDE4CPDE4DADORA2AADORA1 | |
| SCHEMBL20517233 | 0.77 | PDE4A (0.40) | PDE4APDE4CPDE4DADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178668-B2 | 2-aminopyridine kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2012-05-15 | — | — | US | disclosed |
| EP-2265270-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009099982-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090197862-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197862-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | ERBB2, ABL2, TIE1 | PDE4A 2821/4885PDE4C 3015/4885PDE4D 2968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.